Crispr Therapeutics Stock Jumps 15% In 2 Days After New Blood Disease Drug Fast-TrackedInvestors Business Daily • 05/12/20
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe HemoglobinopathiesGlobeNewsWire • 05/11/20
Why Adaptimmune Therapeutics, Atreca, and CRISPR Therapeutics All Tanked In MarchThe Motley Fool • 04/06/20
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/12/20
CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS RatingInvestors Business Daily • 02/11/20